Circulating tumor DNA–based clinical-genetic (CG) prognostic model for radiographic progression-free survival (rPFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Analysis of Alliance A031201

Authors

• William Kelly

Publication/Presentation Date

5-2026

Volume

44

Issue

16

Published In/Presented At

DOI: 10.1200/JCO.2026.44.16_suppl.5018

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article